Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This
study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3,
randomized, double-blind, placebo control, parallel assignment, 24-week study in the
treatment of ALS. The objectives of this study are to assess the efficacy and safety of
long-term intermittent therapy with 60 mg MCI-186 to ALS patients.